ACLX – arcellx, inc. (US:NASDAQ)
Stock Stats
News
ASH 2024: Arcellx publishes positive results for Anito-cel in multiple myeloma [Yahoo! Finance]
Arcellx, Inc. (NASDAQ: ACLX) had its price target raised by analysts at UBS Group AG from $106.00 to $114.00. They now have a "buy" rating on the stock.
Arcellx, Inc. (NASDAQ: ACLX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $115.00 price target on the stock.
Arcellx, Inc. (NASDAQ: ACLX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $105.00 price target on the stock.
Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition [Yahoo! Finance]
Form 8-K Arcellx, Inc. For: Dec 09
Form 8-K Arcellx, Inc. For: Dec 08
Form 4 Arcellx, Inc. For: Dec 03 Filed by: Patel Kavita
Form SC 13G Arcellx, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Form 4 Arcellx, Inc. For: Nov 15 Filed by: Gilson Michelle
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.